Markets Tread Water as Crypto, Biotech Heat Up

Good Thursday morning—here’s a clear-eyed look at what matters before the bell rings.

Market Commentary

The spike in crypto infrastructure stocks after Crypto exchange Bullish rises on second-quarter earnings beat (Cointelegraph) is grabbing headlines, but what scouts are overlooking is the looming regulatory audit on exchanges. If Washington’s push for tougher crypto rules accelerates, these names could fumble their damn gains. Don’t get blindsided by the euphoria; keep one eye on policy calendars.

It may seem odd, but the bloodletting in Big Tech—over 166,000 layoffs this year (Mass Carnage: The Tech Industry Has Laid Off More Than 166,000 Workers So Far In 2025, Theeconomiccollapseblog.com)—and Biocon’s FDA nod on osteoporosis therapies (Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs, The Times of India) actually share a theme: corporate survival via ruthless cost control and regulatory catalysts. One industry sheds workers to protect margins while another leans on approvals to fuel multiday runs. It underscores a bifurcated market where cash-rich drug makers and lean tech outfits both vie for your capital.

Here’s a straightforward move: dial back on high-octane FAANG and SaaS plays until we see signs layoffs end or cost efficiencies materialize. Meanwhile, stock up on biotech and crypto infrastructure names with tangible catalysts—position for the next FDA announcement or earnings beat. If Martin Shkreli’s short squeeze narrative kicks off, lock in profits on speculative plays and rotate into higher-probability setups.